Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy - Drug Trials For Money - Paid Clinical Trials

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy
Conditions:   Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent High Grade B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma;   Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma;   Refractory Aggressive B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory High Grade B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma;   Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Intervention:   Other: Electronic Health Record Review
Sponsor:   M.D. Anderson Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 5, 2021 / by / in
Comments